SCHEMBL20969682

SCHEMBL20969682

COc1ccc(CCN(Cc2ccc(C(=O)O)cc2)c2nc3cccc(F)c3s2)cc1

nearest known ligand 0.70

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KARS1 Q15046 1/20 0.70
LPAR1 Q92633 6/20 0.48
LPAR5 Q9H1C0 6/20 0.48
TAS2R14 Q9NYV8 5/20 0.46
PPARD Q03181 5/20 0.44
ALOX5 P09917 1/20 0.43
PPARG P37231 2/20 0.42
PPARA Q07869 1/20 0.42
PTGES O14684 1/20 0.41
TAS2R8 Q9NYW2 1/20 0.41
CXCR3 P49682 1/20 0.41
NPC1 O15118 1/20 0.41
POLB P06746 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20969601 0.92 KARS1 (0.59) KARS1LPAR1LPAR5TAS2R14PPARD
SCHEMBL20969751 0.92 KARS1 (0.59) KARS1LPAR1LPAR5TAS2R14PPARD
SCHEMBL20969641 0.91 KARS1 (0.59) KARS1LPAR1LPAR5TAS2R14PPARD
SCHEMBL20969618 0.91 KARS1 (0.60) KARS1LPAR1LPAR5PPARDALOX5
SCHEMBL31130495 0.91 KARS1 (0.57) KARS1PPARDPPARGPPARA
SCHEMBL20969554 0.90 KARS1 (0.55) KARS1LPAR1LPAR5PPARDALOX5
SCHEMBL20969715 0.90 KARS1 (0.57) KARS1LPAR1LPAR5TAS2R14PPARD
SCHEMBL20969608 0.90 KARS1 (0.57) KARS1LPAR1LPAR5PPARDALOX5
SCHEMBL20969689 0.90 KARS1 (0.71) KARS1LPAR1LPAR5TAS2R14PPARD
SCHEMBL31130536 0.90 KARS1 (0.57) KARS1PPARDPPARGPPARACXCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3483149-B1 BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME YUHAN CORP (KR) 2021-01-13 EP claimed
US-10383859-B2 Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same YUHAN CORPORATION (KR) 2019-08-20 US claimed
US-20190142809-A1 Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same YUHAN CORPORATION (KR) 2019-05-16 US claimed
EP-3483149-A1 BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME Yuhan Corporation (KR) 2019-05-15 EP claimed
US-11378572-B2 Therapeutic agent for immune cell migration-caused disease and method for screening same ZYMEDI CO., LTD. (KR) 2022-07-05 US disclosed
US-11378572-B2 Therapeutic agent for immune cell migration-caused disease and method for screening same ZYMEDI CO., LTD. (KR) 2022-07-05 US disclosed
EP-3483149-B1 BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME YUHAN CORP (KR) 2021-01-13 EP disclosed
CN-111629752-A Pharmaceutical composition for preventing or treating cell migration-related diseases comprising, as an active ingredient, an antibody that specifically binds to the N-terminus of lysyl-tRNA synthetase 医药生命融合研究团 2020-09-04 CN disclosed
US-20200141923-A1 THERAPEUTIC AGENT FOR IMMUNE CELL MIGRATION-CAUSED DISEASE AND METHOD FOR SCREENING SAME ZYMEDI CO., LTD. (KR) 2020-05-07 US disclosed
US-20200141923-A1 THERAPEUTIC AGENT FOR IMMUNE CELL MIGRATION-CAUSED DISEASE AND METHOD FOR SCREENING SAME ZYMEDI CO., LTD. (KR) 2020-05-07 US disclosed
US-10383859-B2 Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same YUHAN CORPORATION (KR) 2019-08-20 US disclosed
US-20190142809-A1 Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same YUHAN CORPORATION (KR) 2019-05-16 US disclosed
EP-3483149-A1 BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME Yuhan Corporation (KR) 2019-05-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11378572-B2 Therapeutic agent for immune cell migration-caused disease and method for screening same NFATC1, MIF, MMP8 KARS1 193/4885LPAR1 799/4885LPAR5 922/4885
US-20190142809-A1 Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same ILK, SBDS, BDKRB1 KARS1 6/4885LPAR1 567/4885LPAR5 670/4885
US-10383859-B2 Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same ILK, SBDS, BDKRB1 KARS1 6/4885LPAR1 567/4885LPAR5 670/4885
US-20200141923-A1 THERAPEUTIC AGENT FOR IMMUNE CELL MIGRATION-CAUSED DISEASE AND METHOD FOR SCREENING SAME NFATC1, MIF, MMP8 KARS1 193/4885LPAR1 799/4885LPAR5 922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.